XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Operating Segments (Tables)
 6 Months Ended 12 Months Ended
Jun. 30, 2014
Dec. 31, 2013
Operating Segments [Abstract]    
Summary of segmental information

 		 Three Months Ended 
June 30,		  
    2014     2013  
Contract/Grant Revenue                
Vaccines/BioDefense   $ 1,321,385     $ 588,496  
BioTherapeutics     96,863       43,782  
Total   $ 1,418,248     $ 632,278  
                 
Income (Loss) from Operations                
Vaccines/BioDefense   $ 264,810     $ (1,532,472 )
BioTherapeutics     (650,477 )     (530,640 )
Corporate     (1,310,164 )     (692,772 )
Total   $ (1,695,831 )   $ (2,755,884 )
                 
Amortization and Depreciation Expense                
Vaccines/BioDefense   $ 9,809     $ 27,968  
BioTherapeutics     49,072       28,675  
Corporate     1,526       424  
Total   $ 60,407     $ 57,067  
                 
Other Income /(Expense), Net                
Corporate   $ 747,314     $ (649,273 )
                 
Stock-Based Compensation                
Vaccines/BioDefense   $ 10,450     $ 11,128  
BioTherapeutics     33,135       25,905  
Corporate     77,672       47,755  
Total   $ 121,257     $ 84,788  

  

    Six Months Ended 
June 30,		  
    2014     2013  
Revenues, Principally from Grants            
Vaccines/BioDefense   $ 2,198,430     $ 1,418,345  
BioTherapeutics     130,415       114,287  
Total   $ 2,328,845     $ 1,532,632  
                 
Income (Loss) from Operations                
Vaccines/BioDefense   $ 404,214     $ (1,563,467 )
BioTherapeutics     (1,686,068 )     (988,266 )
Corporate     (2,003,886 )     (1,292,048 )
Total   $ (3,285,740 )   $ (3,843,781 )
                 
Amortization and Depreciation Expense                
Vaccines/BioDefense   $ 19,744     $ 55,635  
BioTherapeutics     99,011       57,070  
Corporate     3,739       861  
Total   $ 122,494     $ 113,566  
                 
Other Income /(Expense), Net                
Corporate   $ (994,485 )   $ (648,790 )
                 
Stock-Based Compensation                
Vaccines/BioDefense   $ 20,900     $ 22,249  
BioTherapeutics     109,256       46,941  
Corporate     167,763       95,090  
Total   $ 297,919     $ 164,280  

 

    As of 
June 30, 
2014		     As of 
December 31, 
2013		  
             
Identifiable Assets                
Vaccines/BioDefense   $ 702,507     $ 1,870,414  
BioTherapeutics     313,022       386,721  
Corporate     5,130,406       6,008,320  
Total   $ 6,145,935     $ 8,265,455  
   
For the Year Ended December 31,
 
   
2013
  
2012
 
Revenues
      
Vaccines/BioDefense
 $3,003,822  $2,919,677 
BioTherapeutics
  220,330   224,943 
                       Total
 $3,224,152  $3,144,620 
         
Loss from Operations
        
Vaccines/BioDefense
 $(1,666,130) $(33,636)
BioTherapeutics
  (3,069,998 )  (2,203,721 )
Corporate
  (2,420,414 )  (2,453,311 )
                       Total
 $(7,156,542) $(4,690,668)
          
Amortization and Depreciation Expense
        
Vaccines/BioDefense
 $37,981  $38,589 
BioTherapeutics
  190,033   190,003 
Corporate
  2,057   2,038 
                       Total
 $230,071  $230,630 
          
Interest Income 
        
Corporate 
 $1,960  $6,202 
          
Stock-Based Compensation
        
Vaccines/BioDefense
 $80,432  $44,484 
BioTherapeutics 
  250,431   84,020 
Corporate 
  472,197   333,666 
                        Total 
 $803,060  $462,170 
 
   
As of December 31,
 
   2013  2012 
          
Identifiable Assets
        
Vaccines/BioDefense
 $1,870,414  $628,494 
BioTherapeutics
  386,721   566,111 
Corporate
  6,008,320   3,510,499 
                       Total
 $8,265,455  $4,705,104